Search

Search Constraints

You searched for: Author/Creator Traverse, Jay H.

Search Results

2. A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. Issue 6 (28th August 2015)

3. A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial. (13th April 2021)

4. ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. Issue 2 (February 2017)

5. Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study. Issue 9 (September 2016)

6. Bone Marrow Characteristics Associated With Changes in Infarct Size After STEMI. Issue 1 (2nd January 2015)

7. Bone Marrow Characteristics Associated With Changes in Infarct Size After STEMI: A Biorepository Evaluation From the CCTRN TIME Trial. Issue 1 (2nd January 2015)

8. CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina. (12th June 2020)